Cervical Cancer 2022
DOI: 10.1136/ijgc-2022-esgo.31
|View full text |Cite
|
Sign up to set email alerts
|

2022-RA-582-ESGO Lymphoepithelioma-like carcinoma of the uterine cervix: A-three case study

Abstract: Whatever the screening frequency, in both strategies, about 50% of costs were related to Self-HPV testing, while for the Self-HPV/VIA strategy, triage accounted for approximately 1% of costs. At equal frequencies, costs of precancerous treatment were higher in Self-HPV than Self-HPV/VIA strategies, due to high overtreatment rate of CIN1 in the absence of triaging. The costs of cancer treatment were comparable in both strategies. Conclusion Cost-effectiveness depends on the type and frequency of screening. Thes… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles